Wearable cardiac monitoring is catching arrhythmias in men who would never have scheduled the test that found them
Dr. Dereck Mush, MD, MBA
Sava Technologies
Wearable microsensor that continuously measures molecules just beneath the skin, starting with glucose.
What they do
Sava develops a minimally invasive wearable biosensor platform that samples interstitial fluid to continuously monitor glucose and other molecules. Its microsensor filament is roughly a tenth the length of a conventional CGM filament. The company raised a $36M Series B in October 2026 led by Ascensia Diabetes Care, which also took exclusive European distribution rights, bringing total funding to $68M. Sava is planning a pivotal clinical study and is targeting CE approval for non-adjunctive use within 18 to 24 months.
The record
- Vertical
- Remote Monitoring & Wearables
- Sub-segment
- Wearable biosensors
- Product type
- Device
- Stage
- Series B
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2019
- Total funding
- $68M raised
Notable investors: Ascensia Diabetes Care, Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures.
Also in Remote Monitoring & Wearables
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Non-Invasive Neural Race: Why Apple Absorbed Sonera to Bypass the Skin Barrier
Dr. Dereck Mush, MD, MBA
Wearables are quietly becoming clinical alerting systems, not just fitness trackers
Dr. Dereck Mush, MD, MBA
Consumer sleep tracking has never been more precise. Diagnosing sleep disorders still requires a lab
Dr. Dereck Mush, MD, MBA